Sambria Pharmaceuticals topical anesthetics that are all part of its growing brand that include the Company’s proprietary topical delivery system technology. The topical anesthetics line is the first of many topically applied medications that are planned for entry into the medical and consumer healthcare markets. The delivery system is designed to assist active pharmaceutical ingredients (API’s) rapidly penetrate the skin while also limiting system entry.
The launch topical anesthetic line is designed to rapidly enter the skin while not entering the system with the intact API’s, which are lidocaine, benzocaine and tetracaine. In an approved study of the NeuroMed 7 (4% topical lidocaine) there was no analytic evidence of the API entering the blood of over 230 human blood samples of test subjects who were treated with the anesthetic agent. The Company will be studying other therapeutic agents that it will include in its proprietary chemical delivery system. Many medicines, both over the counter (OTC) and prescription, can supply the therapeutic effect required but also can cause a health risk when to much enters into the circulatory system. The advantage of creating a delivery system that limits entry of these API’s can serve the purpose of reducing the risks associated with cumulative systemic absorption. Topical anesthetics for example can lead to serious adverse health events when toxic levels build up in the blood stream including death. By limiting systemic absorption, this risk can be reduced.
Stay tuned for the market entry of new Sambria Pharmaceuticals products, scheduled for year-end 2017!
This information is not intended to be used to diagnose or treat medical conditions. Consult a licensed physician prior to using NeuroMed Topical Anesthetics or other topical anesthetic brands.